EnVivo: anti Alzheimer’s compound
(gamma secretase modulator)
Please Help Support Alzheimer's Research Today!
Your Alzheimer's donation will help billions live without it.
When Eli Lilly stopped developing an Alzheimer’s compound a year ago due to side effects and lack of effectiveness, some experts expressed doubt about a similar drug being developed by Watertown-based EnVivo Pharmaceuticals. Those doubts may have intensified last week, when pharmaceutical giant Lilly released more data on the drug, called semagacestat, which is in a drug class known as gamma secretase inhibitors. During the Alzheimer’s Association International Conference in Paris, a senior medical director for Lilly said patients taking semagacestat experienced worse cognitive functioning than did patients taking the placebo - even seven months after they stopped taking the drug. But EnVivo chief executive Kees Been is undeterred. EnVivo moved its own gamma secretase-targeting drug, EVP-0962, into Phase 1 testing on June 27. In animal trials, the company said, the drug reduced brain inflammation caused by Alzheimer’s, reversed behavioral defects, and appeared to have a better safety profile than gamma secretase inhibitors.
Gamma secretase is an enzyme that contributes to the buildup of amyloid plaques in the brain, a major feature of Alzheimer’s. The problem, Been said, is that the enzyme serves many functions in the body. “If you inhibit it, you can create all kinds of side effects,’’ he said.
For example, gamma secretase is critical for the processing of a protein called Notch, which controls cell differentiation and communication. By inadvertently inhibiting Notch, semagacestat may have touched off the severe gastrointestinal side effects seen in some Lilly patients, Been said. Participants in Lilly’s trial also faced a higher risk of developing skin cancer. Continue to read: boston.com
Waste could provide nano fibres for probiotics